Inclusion Criteria:

- Able to read consent form and give informed consent.

- At least 15 years old.

- Histologically confirmed non-lymphoid hematological malignancy.

- Recipient of T cell depleted bone marrow (BM) or peripheral blood stem cell (PBSC)
transplant from a 6/6 HLA (A, B, DR by intermediate resolution) identical related or
unrelated donor after myeloablative conditioning.

- Received TCD HCT containing < 1x105 CD3+ T cells/kg of recipient.

- Patient included in at least one of the following categories:

- AML in 2nd or greater complete remission.

- High-risk AML (high-risk cytogenetics, undifferentiated leukemia, secondary AML,
antecedent MDS) in 1st remission.

- CML in 2nd or greater chronic phase, 2nd or greater accelerated phase.

- MDS intermediate or high risk by IPSS criteria.

- History of opportunistic infection (CMV viremia requiring anti-viral therapy, PCP
pneumonia, mycobacterial infection, herpes zoster, viral respiratory infection
(influenza, RSV, para-influenza), etc.

- CD4+ T cell count < 100 at 6 months post-transplant.

- At high risk for opportunistic infection (e.g., history of treated invasive fungal
infection prior to the transplantation, positive CMV serology in patient, or positive
toxoplasmosis serology in donor and patient, etc.).

- 60 - 210 days post transplant.

- In remission at the time of initiation of CYT107.

- Documented engraftment with sustained neutrophil counts of at least 1000/mcl and
untransfused platelet counts > 20 000/mcl for 3 consecutive lab values (the last one
tested <10 days before initiation of treatment) on 3 different days prior to
treatment. Patients who have engrafted but require G-CSF for myelosuppressive
antibiotics or antiviral medications are eligible if they require G-CSF no more than
twice weekly and their ANC remains >1000/mcl.

- KPS > 60%.

- Adequate organ function:

- Cardiac: No evidence of change in cardiac function by history, exam and/or EKG
post-HCT.

- Pulmonary: Absence of dyspnea or hypoxia (< 90% of saturation by pulse oxymetry
on room air).

- Hepatic: Bilirubin <= 1.5 X ULN, AST (SGOT) and /or ALT (SGPT) <= 2.5 X ULN.
PT/PTT < 1.5 X ULN.

- Renal: Calculated Creatinine clearance > 60 mL/min/1.73 m2. [Note: all
transplant patients had an ejection fraction of > 40% on their pre-transplant
echocardiogram and a DLCO > 50% of predicted (corrected for hemoglobin)]

Exclusion Criteria:

- No evidence or history of acute GVHD or of chronic GVHD.

- No recurrent leukemia post HCT.

- No active uncontrolled viral, bacterial or fungal infection.

- No documented HIV-1 or -2, HBV or HCV infection at any time before or after
transplant (a positive hepatitis B serology indicative of a previous immunization is
not an exclusion criteria).

- Not be receiving systemic corticosteroid, anti-mitotic agent or other
immunosuppressive treatment.

- Not receiving Growth Hormone or gonadotropin agonists/ antagonists.

- Not receiving any cytokine support other than G-CSF post-HCT.

- Not receiving concurrent treatment with another investigational drug and/or
biological agent.

- Not receiving anticoagulant therapy.

- No uncontrolled hypertension.

- No history of lymphoid malignancy (e.g. Hodgkin disease, non Hodgkin lymphoma, Acute
Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia) or acute biphenotypic
leukemia.

- No peripheral lymphadenopathy (any lymph node > 1 cm).

- No history of EBV associated lymphoproliferation.

- No EBV viremia equal to or greater than 500 copies EBV DNA/mL of blood by
quantitative PCR.

- No history of autoimmune disease nor a HCT donor with a history of an autoimmune
disease.

- Fertile patients must use effective birth control. Not pregnant or nursing. Negative
pregnancy test within 2 weeks of study treatment.

- QTc prolongation (QTc > 470 ms) or prior history of significant arrhythmia or ECG
abnormalities.

- No active drug or alcohol use or dependence that, in the opinion of the investigator,
would interfere with adherence to study requirements.

- Any past or current psychiatric illness that, in the opinion of the investigator,
would interfere with adherence to study requirements or the ability and willingness
to give written informed consent.